WMS 2023 poster presentation: Age at loss of ambulation in patients with DMD from the STRIDE Registry and the CINRG Natural History Study: A matched cohort analysis
This poster presentation, given as part of WMS 2023, explores the effect of ataluren on age at loss of ambulation vs standard of care (SoC) alone on patients with nonsense mutation Duchenne muscular dystrophy (nmDMD)
Explore the demographics of patients in the STRIDE Registry and CINRG Natural History Study
Discover the effect of ataluren on the age at loss of ambulation in patients with this rare disease
Understand the effectiveness of combined treatment with ataluren and SoC by comparing age at loss of ambulation data across the different patient groups
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at firstname.lastname@example.org.
Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.
This poster presentation was developed and funded by PTC Therapeutics for WMS 2023.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2300184 | January 2024
Sign in or register to access exclusive content on this site